AU2017298984B2 - Methods of purifying Fc-containing proteins - Google Patents

Methods of purifying Fc-containing proteins Download PDF

Info

Publication number
AU2017298984B2
AU2017298984B2 AU2017298984A AU2017298984A AU2017298984B2 AU 2017298984 B2 AU2017298984 B2 AU 2017298984B2 AU 2017298984 A AU2017298984 A AU 2017298984A AU 2017298984 A AU2017298984 A AU 2017298984A AU 2017298984 B2 AU2017298984 B2 AU 2017298984B2
Authority
AU
Australia
Prior art keywords
protein
temperature
elution buffer
region
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017298984A
Other languages
English (en)
Other versions
AU2017298984A1 (en
Inventor
John K. KAWOOYA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen Inc
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of AU2017298984A1 publication Critical patent/AU2017298984A1/en
Application granted granted Critical
Priority to AU2023222915A priority Critical patent/AU2023222915B2/en
Publication of AU2017298984B2 publication Critical patent/AU2017298984B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/34—Size-selective separation, e.g. size-exclusion chromatography; Gel filtration; Permeation
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 and B01D15/30 - B01D15/36, e.g. affinity, ligand exchange or chiral chromatography
    • B01D15/3804—Affinity chromatography
    • B01D15/3809—Affinity chromatography of the antigen-antibody type, e.g. protein A, G or L chromatography
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/42—Selective adsorption, e.g. chromatography characterised by the development mode, e.g. by displacement or by elution
    • B01D15/424—Elution mode
    • B01D15/426—Specific type of solvent
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/34—Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Water Supply & Treatment (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Storage Device Security (AREA)
AU2017298984A 2016-07-22 2017-07-21 Methods of purifying Fc-containing proteins Active AU2017298984B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2023222915A AU2023222915B2 (en) 2016-07-22 2023-08-31 Methods of purifying Fc-containing proteins

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662365943P 2016-07-22 2016-07-22
US62/365,943 2016-07-22
PCT/US2017/043384 WO2018018011A2 (en) 2016-07-22 2017-07-21 Methods of purifying fc-containing proteins

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2023222915A Division AU2023222915B2 (en) 2016-07-22 2023-08-31 Methods of purifying Fc-containing proteins

Publications (2)

Publication Number Publication Date
AU2017298984A1 AU2017298984A1 (en) 2019-02-07
AU2017298984B2 true AU2017298984B2 (en) 2023-08-31

Family

ID=59656168

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2017298984A Active AU2017298984B2 (en) 2016-07-22 2017-07-21 Methods of purifying Fc-containing proteins
AU2023222915A Active AU2023222915B2 (en) 2016-07-22 2023-08-31 Methods of purifying Fc-containing proteins

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2023222915A Active AU2023222915B2 (en) 2016-07-22 2023-08-31 Methods of purifying Fc-containing proteins

Country Status (12)

Country Link
US (1) US11312745B2 (enExample)
EP (1) EP3487867B1 (enExample)
JP (2) JP7092744B2 (enExample)
KR (2) KR102435801B1 (enExample)
CN (2) CN115925780B (enExample)
AU (2) AU2017298984B2 (enExample)
CA (2) CA3031469C (enExample)
IL (2) IL285146B (enExample)
MA (1) MA45721A (enExample)
MX (2) MX2019000903A (enExample)
SG (1) SG11201900573UA (enExample)
WO (1) WO2018018011A2 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202102713TA (en) * 2018-09-21 2021-04-29 Teneobio Inc Methods for purifying heterodimeric, multispecific antibodies
MX2021003976A (es) 2018-10-11 2021-05-27 Amgen Inc Procesamiento posterior de constructos de anticuerpos biespecificos.
SG11202106370WA (en) * 2019-01-16 2021-07-29 Regeneron Pharma Method and system of identifying and quantifying antibody fragmentation
KR102286892B1 (ko) * 2019-07-08 2021-08-06 삼천당제약주식회사 안과용 단백질 제제의 정제방법
CN110724204B (zh) * 2019-11-18 2021-10-22 广东菲鹏制药股份有限公司 Fc融合蛋白的纯化方法
CN112881675A (zh) * 2019-11-29 2021-06-01 广东菲鹏生物有限公司 IgM抗体检测稀释液
WO2021207657A1 (en) 2020-04-09 2021-10-14 Cytomx Therapeutics, Inc. Compositions containing activatable antibodies
WO2022061035A1 (en) * 2020-09-16 2022-03-24 Waters Technologies Corporation Improved size exclusion chromatography utilizing low concentration amino acids in size exclusion chromatography mobile phase
EP4421089A4 (en) * 2021-10-19 2026-01-07 Alteogen Inc METHOD FOR PURIFYING A FUSION PROTEIN HAVING AN IGG FC DOMAIN
CN113980092B (zh) * 2021-12-09 2024-05-14 上海药明生物技术有限公司 一种蛋白质亲和纯化方法
CN116165290B (zh) * 2021-12-17 2025-06-27 复旦大学 一种抗体药物研发流程中工程细胞株的筛选方法
CN116271982B (zh) * 2022-11-30 2024-01-09 杭州广科安德生物科技有限公司 一种血液高丰度蛋白免疫亲和柱的再生方法
EP4634201A1 (en) * 2022-12-12 2025-10-22 H. Lundbeck A/S Arginine wash in protein purification

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008143199A1 (ja) * 2007-05-21 2008-11-27 Nomadic Bioscience Co., Ltd. 新規ポリペプチド，アフィニティークロマトグラフィー用材，及びイムノグロブリンの分離及び／又は精製方法

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4968607A (en) 1987-11-25 1990-11-06 Immunex Corporation Interleukin-1 receptors
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
WO1990005183A1 (en) 1988-10-31 1990-05-17 Immunex Corporation Interleukin-4 receptors
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6713610B1 (en) 1990-01-12 2004-03-30 Raju Kucherlapati Human antibodies derived from immunized xenomice
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
WO1991018982A1 (en) 1990-06-05 1991-12-12 Immunex Corporation Type ii interleukin-1 receptors
US5350683A (en) 1990-06-05 1994-09-27 Immunex Corporation DNA encoding type II interleukin-1 receptors
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
ES2301158T3 (es) 1992-07-24 2008-06-16 Amgen Fremont Inc. Produccion de anticuerpos xenogenicos.
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US6130364A (en) 1995-03-29 2000-10-10 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
CA2219361C (en) 1995-04-27 2012-02-28 Abgenix, Inc. Human antibodies derived from immunized xenomice
EP1972194A1 (en) 1996-12-03 2008-09-24 Amgen Fremont Inc. Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefrom
US6271349B1 (en) 1996-12-23 2001-08-07 Immunex Corporation Receptor activator of NF-κB
WO1999053059A1 (en) * 1998-04-16 1999-10-21 Genentech, Inc. Secretion of glycosylated proteins using a tissue plasminogen activator pro-sequence
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
EP1805320B1 (en) 2004-10-22 2014-09-03 Amgen Inc. Methods for refolding of recombinant antibodies
BRPI0611600B8 (pt) * 2005-06-17 2021-05-25 Wyeth Corp método para purificação de uma proteína tendo uma região fc a partir de um líquido fonte compreendendo a proteína e uma ou mais impurezas, e kit
WO2007081906A2 (en) * 2006-01-06 2007-07-19 Amgen Inc. Purification by column-chromatography using eluants containing organic solvents
CN105837690A (zh) 2006-06-12 2016-08-10 新兴产品开发西雅图有限公司 具有效应功能的单链多价结合蛋白
US10982250B2 (en) * 2006-09-18 2021-04-20 Genentech, Inc. Methods of protein production
EP3663318A1 (en) 2008-01-07 2020-06-10 Amgen Inc. Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
JP5529869B2 (ja) * 2008-08-14 2014-06-25 メルク・シャープ・アンド・ドーム・コーポレーション プロテインａアフィニティークロマトグラフィーを用いる抗体の精製方法
SG176963A1 (en) 2009-06-22 2012-02-28 Amgen Inc Refolding proteins using a chemically controlled redox state
LT3660032T (lt) * 2009-06-25 2026-02-25 Amgen Inc. Ne žinduolių sistemoje ekspresuotų baltymų surišamojo gryninimo būdai
CN102712696A (zh) * 2009-09-16 2012-10-03 弗·哈夫曼-拉罗切有限公司 包含卷曲螺旋和/或系链的蛋白质复合体及其用途
CN102382190B (zh) * 2010-09-01 2014-04-09 山东新时代药业有限公司 分离和去除TNFR-Fc融合蛋白中寡聚体的方法
US20130317172A1 (en) 2010-12-24 2013-11-28 Nomadic Bioscience Co., Ltd. Method for immobilizing temperature responsive protein a
JP6280499B2 (ja) 2011-07-08 2018-02-14 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． Ｆｃ融合タンパク質の精製方法
JP6420756B2 (ja) * 2012-03-28 2018-11-07 ジーイー・ヘルスケア・バイオプロセス・アールアンドディ・アクチボラグ アフィニティークロマトグラフィーマトリックス
EP2889617B1 (en) 2012-08-27 2017-10-11 Asahi Kasei Medical Co., Ltd. Antibody purification method by means of temperature-responsive chromatography
UY35148A (es) * 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
US20140302037A1 (en) 2013-03-15 2014-10-09 Amgen Inc. BISPECIFIC-Fc MOLECULES
AP2016009222A0 (en) * 2013-11-04 2016-05-31 Glenmark Pharmaceuticals Sa Production of t cell retargeting hetero-dimeric immunoglobulins

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008143199A1 (ja) * 2007-05-21 2008-11-27 Nomadic Bioscience Co., Ltd. 新規ポリペプチド，アフィニティークロマトグラフィー用材，及びイムノグロブリンの分離及び／又は精製方法

Also Published As

Publication number Publication date
US20190127418A1 (en) 2019-05-02
AU2023222915A1 (en) 2023-09-21
SG11201900573UA (en) 2019-02-27
KR20220120716A (ko) 2022-08-30
JP2019528255A (ja) 2019-10-10
EP3487867A2 (en) 2019-05-29
KR102579850B1 (ko) 2023-09-18
JP2022120138A (ja) 2022-08-17
EP3487867B1 (en) 2026-04-01
JP7411020B2 (ja) 2024-01-10
CN109563125A (zh) 2019-04-02
AU2017298984A1 (en) 2019-02-07
AU2023222915B2 (en) 2026-01-22
MX2019000903A (es) 2019-05-15
MX2023006291A (es) 2023-06-13
CN115925780A (zh) 2023-04-07
CA3031469C (en) 2025-11-18
MA45721A (fr) 2019-05-29
EP3487867C0 (en) 2026-04-01
CA3218290A1 (en) 2018-01-25
IL285146A (en) 2021-08-31
US11312745B2 (en) 2022-04-26
WO2018018011A2 (en) 2018-01-25
JP7092744B2 (ja) 2022-06-28
CN115925780B (zh) 2025-11-04
IL264375A (en) 2019-02-28
CA3031469A1 (en) 2018-01-25
IL285146B (en) 2022-09-01
IL264375B (en) 2021-09-30
KR20190037247A (ko) 2019-04-05
KR102435801B1 (ko) 2022-08-25
CN109563125B (zh) 2022-08-09
WO2018018011A3 (en) 2018-03-01

Similar Documents

Publication Publication Date Title
AU2023222915B2 (en) Methods of purifying Fc-containing proteins
US9957318B2 (en) Protein purification methods to reduce acidic species
US9708400B2 (en) Methods to modulate lysine variant distribution
CA2805132C (en) Purification of antibody fragments
US20160115193A1 (en) Novel purification of antibodies using hydrophobic interaction chromatography
US20130336957A1 (en) Novel purification of human, humanized, or chimeric antibodies using protein a affinity chromatography
WO2012125735A1 (en) An integrated approach to the isolation and purification of antibodies
AU2018326458B2 (en) Method for purifying proteins
CA2603408A1 (en) Methods for producing polypeptides by regulating polypeptide association
US20200165295A1 (en) Method for purifying anti-il-6 receptor antibodies

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)